摘要
目的通过对血清和尿中亮氨酸氨基肽酶(leucine aminopeptidase,LAP)活性的同时检测,探讨其临床意义。方法采用酶速率法同时检测32例患者的血清和尿液LAP。结果血清检测结果明显增高的有19例,均为肝病(肝硬化7例,肝癌5例,慢性肝炎5例,胆汁淤积2例)。尿液检测结果明显增高的有13例,均为肾病(糖尿病肾损害7例,高血压肾损害4例,药物性损害2例)。血清中LAP活性明显升高者,大多为肝胆病患者。尿液中LAP活性明显升高者,大多为肾病患者。结论血清和尿液LAP同时检测,血清检测活性增高提示肝胆病,尿液检测活性增高提示肾病,差异显著,可作为临床早期诊断肝病和肾病的重要依据。
Objective To explore clinical significance of the test of leucine aminopeptidase（leucine aminopeptidase, LAP） in serum and urine at the same time. Methods 32 patients were tested for LAP in serum and urine at the same time using enzyme velocity method. Results The results of the sera diagnosis higher obviously in 19 cases, they were all liver disease（7 cases of cirrhosis, 5 cases of liver cancer, 5 cases of chronic hepatitis and 2 cases of cholestasis）. 13 cases were higher significantly in urine test, they were all kidney disease. The cases LAP were higher obviously in serum most were liver and gallbladder disease, but most are kidney disease higher in urine. Conclusion Serum LAP activity increased significantly suggests liver disease and urine LAP activity increased significantly suggests kidney disease, can be used as the primary basis of the early diagnosis of liver and kidney disease.
出处
《中国继续医学教育》
2015年第7期162-163,共2页
China Continuing Medical Education
关键词
亮氨酸氨基肽酶
血清
尿
肝病和肾病
Leucine aminopeptidase
Serum
Urine
Liver and kidney disease
